Dr. Beck brings more than 24 years of diversified industry experience in animal physiology, animal science, toxicology and safety pharmacology; including 11 years of increasing levels of leadership within the CRO industry. Most recently Dr. Beck has held positions at Covance Laboratories and was formerly with SNBL USA. He has also held positions at the Washington Regional Primate Center, Ohio State University and Battelle Memorial Institute. Through his experience Dr. Beck has gained a full understanding of what it takes to direct nonclinical GLP and non-GLP studies supporting drug development processes, and will provide leadership, oversight, and strategic operational alignment that fulfill SNBL USA business objectives in his new position.
“We are pleased that Dr. Beck has agreed to rejoin SNBL USA,” said Takeshi ‘KC’ Yamakawa, SNBL USA CEO. “Tom’s background and perspectives will be a significant asset to our team and we believe his understanding of the CRO industry and drug development process in general will increase the value of the services that SNBL USA provides to our clients.” Dr. Beck holds a BS and MS in Animal Science, Reproductive Physiology from Washington State University and a PhD in Neuroendocrinology, Physiology from Michigan State University.
For more information regarding SNBL USA or SNBL Group of companies, contact SNBL USA today via info@snblusa.com or +1 (425) 322.1950.
About SNBL USA, Ltd.
Headquartered in Everett, WA, SNBL USA, Ltd. is a preclinical CRO that specializes in nonhuman primate (NHP) and small animal research. Study programs range from regulatory toxicology to customized study designs and disease models. Specialized programs include reproductive toxicology, safety pharmacology, immunotoxicology and carcinogenicity. SNBL USA’s Laboratory Services division intelligently applies extensive experience, comprehensive scientific capabilities, and modern technology to bring outstanding support to all client research. SNBL USA SRC complements SNBL USA in providing quality NHP resources. Through a commitment to investment and excellence, SNBL USA strives to offer the biotechnology and pharmaceutical industries unparalleled quality in both science and service. For additional information call 425.407.0121 or visit www.snblusa.com.
SNBL USA is a wholly-owned subsidiaries of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. Established in 1957, SNBL currently employs approximately 2,000 team members worldwide and provides full service drug development capabilities ranging preclinical through clinical services.
